(00:32)
 Could you provide a little bit of background about yourself, please?

(01:01)
 Please give us a brief overview of the new PIK3CA assay.
 
(02:09) 
 Why do we offer two different tests, and when should each be ordered?

(03:58)
 Which patients should have this testing?

(04:39)
 Is this testing used for patients being considered for second-line treatment after first-line hormone receptor treatment?

(05:20)
 Is there anything else you would like to add about the PIK3CA testing?

(06:23)
 Why is it important to know the molecular signature of these tumors?